37538-68-4Relevant articles and documents
PYRIDOPYRIMIDINES AND METHODS OF THEIR USE
-
Page/Page column 57, (2021/12/28)
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
-
Paragraph 0213; 0214, (2021/01/25)
The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
Trisubstituted pyrido[2,3-D]pyrimidines, methods for preparing same and therapeutic uses thereof
-
Page/Page column 58, (2019/02/20)
The present invention relates to compounds of the following general formula (I): wherein: R1 is notably a group —NRaRb, Ra and Rb forming together with the nitrogen atom onto which they are bound, a h
Application of quinazoline and pyrido[3,2-: D] pyrimidine templates to design multi-targeting agents in Alzheimer's disease
Mohamed, Tarek,Mann, Mandeep K.,Rao, Praveen P. N.
, p. 22360 - 22368 (2017/07/10)
A quinazoline and pyrido[3,2-d]pyrimidine based compound library was designed, synthesized and evaluated as multi-targeting agents aimed at Alzheimer's disease (AD). The SAR studies identified compound 8h (8-chloro-N2-isopropyl-N4-ph
2,4-quinazolinediamine derivatives, and preparation method and application thereof
-
Paragraph 0185; 0186; 0187, (2017/04/18)
The invention discloses 2,4-quinazolinediamine derivatives, and a preparation method and application thereof, belonging to the field of medicines and preparation and application thereof. The 2,4-quinazolinediamine derivatives comprises compounds as shown in a formula (I) which is described in the specification and a solvate, hydrate, tautomer and pharmaceutically acceptable salt thereof. Test results show that the 2,4-quinazolinediamine derivatives have strong Wolbachia resisting activity; and in the derivatives, 2-isopropylamido substitution has good effect, and compounds with better Wolbachia resisting activity can be obtained by changing a 4-amido group. The compounds have activity in resisting plasmodia, Wolbachia and bacteria.
A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787
Andaloussi, Mounir,Lim, Herman D.,Van Der Meer, Tiffany,Sijm, Maarten,Poulie, Chris B.M.,De Esch, Iwan J.P.,Leurs, Rob,Smits, Rogier A.
, p. 2663 - 2670 (2013/08/14)
In this work we describe the optimization of a lead compound based on the quinazoline template to give a new series of potent pyrido[3,2-d]pyrimidines as histamine H4 receptor antagonists. The pyrido[3,2-d]pyrimidine ligands have significantly reduced hERG binding compared to clinical stage compound PF-3893787 while showing good affinities at the human and rodent histamine receptors. The receptor residence time of several of these new compounds was determined for the human H4R and compared with JNJ7777120 and PF-3893787. The pyrido[3,2-d]pyrimidines showed residence times lower than JNJ7777120 but comparable to the residence time of PF-3893787. Overall, the pyrido[3,2-d]pyrimidines show an excellent in vitro profile that warrants their further investigation in relevant models of human disease.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 00649-00650, (2013/03/26)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Page/Page column 145, (2012/05/21)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES
-
Page/Page column 60-61, (2010/04/27)
This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune deseases, inflammatory disorders, multiple sclerosis and other deseases like cancers.
